Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

News provided by

May 19, 2014, 10:34 ET

NEW YORK, May 19, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options

http://www.reportlinker.com/p02126317/Breast-Cancer-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-HER-2-Positive-Therapies-Provide-Diversified-Treatment-Options.html

Summary

GBI Research, the leading business intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options", which provides in-depth analysis of breast cancer market within the Asia-Pacific (APAC) covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2013, along with market forecast until 2020. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.

The breast cancer therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.5 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.6% to $2.5 billion by 2020. Japan had the largest market in 2013 with a value of $872m, or a share of 58%, followed by China with $320m or 21%, and Australia with $234m or 16%. India had the lowest market share and value at 5% and $81m, but is expected to witness the fastest growth over the forecast period with a CAGR of 13.8%, compared to Australia at 7.8% and China and Japan both at 7.7%.

Scope

The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in the breast cancer therapeutics in the four APAC markets of Australia, China, India and Japan.The report includes -
- Disease overview, as well as treatment algorithms and treatment usage patterns
- Market size and forecast for the APAC breast cancer market from 2013 to 2020
- Major marketed products in the APAC region along with a heat map of product performance
- In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis
- Key drivers and restraints that have had and are expected to have a significant impact upon the market
- Key licensing and co-development agreements that could have impact on growth trends

Reasons to buy

The report will enhance your decision-making capability by allowing you to -
- Align your product portfolio to the markets with high growth potential
- Develop market entry and expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the breast cancer drugs market
- Develop key strategic initiatives based upon an understanding of key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents
2 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 -Introduction 8
2.1 Breast Cancer 8
2.2 Symptoms 8
2.3 Epidemiology 9
2.4 Pathophysiology 10
2.5 Diagnosis 10

2.6 Prognosis and Disease Staging 11
2.6.1 Classification 12
2.7 Treatment Options 13
2.7.1 Surgery and Radiation Therapy 13
2.7.2 Chemotherapy 13
2.7.3 Hormonal Therapies 14
2.7.4 Targeted Therapies 14
2.7.5 Resistance to Pharmacological Therapies 15
2.7.6 Treatment Guidelines 15
2.7.7 Measuring the Effectiveness of Treatment 18
3 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Marketed Products 19
3.1 Key Marketed Products 19
3.1.1 Herceptin 19
3.1.2 Halaven 21
3.1.3 Avastin 21
3.1.4 Gemzar 22
3.1.5 Taxotere 23

3.1.6 Tykerb 24
3.1.7 Femara 25
3.1.8 Aromasin 25
3.1.9 Zoladex 25
3.1.10 Arimidex 26
3.2 Heat Map for Marketed Products 26
4 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Pipeline Analysis 28
4.1 Overall Pipeline 28
4.2 Pipeline Analysis by Molecule Type 30
4.3 Pipeline Analysis by Mechanism of Action 32
4.4 Clinical Trials - Failure Rate 34
4.5 Clinical Trial Size 35
4.6 Duration 37
4.7 Promising Drug Candidates in Pipeline 38
4.7.1 Buparlisib 38
4.7.2 Palbociclib 38
4.7.3 Afatinib dimaleate 38
4.7.4 Entinostat 39
4.7.5 Neratinib 39
4.7.6 BMN-673 40

4.7.7 Etirinotecan pegol 40
5 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Market Forecast to 2020 41
5.1 Asia-Pacific Market 41
5.1.1 Treatment Usage Patterns 41
5.1.2 Market Size 41
5.2 India 43
5.2.1 Treatment Usage Patterns 43
5.2.2 Annual Cost of Therapy 43
5.2.3 Market Size 43
5.3 Australia 45
5.3.1 Treatment Usage Patterns 45
5.3.2 Annual Cost of Therapy 45
5.3.3 Market Size 45

5.4 China 47
5.4.1 Treatment Usage Patterns 47
5.4.2 Annual Cost of Therapy 47
5.4.3 Market Size 47
5.5 Japan 49
5.5.1 Treatment Usage Patterns 49
5.5.2 Annual Cost of Therapy 49
5.5.3 Market Size 49
5.6 Drivers and Barriers for the Breast Cancer Therapeutics in Asia-Pacific Market to 2020 51
5.6.1 Drivers 51
5.6.2 Barriers 52
6 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 – Deals and Strategic Consolidations 53
6.1 Licensing Agreements 53
6.1.1 Major Licensing Deals 56
6.2 Co-development Agreements 57
6.2.1 Major Co-development Agreements 59
7 Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Appendix 61
7.1 All Pipeline Drugs by Phase 61
7.1.1 Discovery 61
7.1.2 Preclinical 64

7.1.3 IND/CTA-Filed and Phase I 76
7.1.4 Phase II 82
7.1.5 Phase III 89
7.1.6 Pre-Registration 92
7.2 Market Forecasts to 2020 92
7.2.1 Asia-Pacific 92
7.2.2 India 92
7.2.3 Australia 93
7.2.4 China 93
7.2.5 Japan 93

7.3 Market Definitions 94
7.4 Abbreviations 94
7.5 References 96
7.6 Research Methodology 99
7.6.1 Coverage 99
7.6.2 Secondary Research 99
7.6.3 Primary Research 100
7.6.4 Therapeutic Landscape 100
7.6.5 Geographical Landscape 102
7.6.6 Pipeline Analysis 103
7.7 Expert Panel Validation 103
7.8 Contact Us 103
7.9 Disclaimer 103

1.1 List of Tables

Table 1: Market for Monoclonal Antibodies in Breast Cancer Therapeutics Market, Global, Tumor, Nodes and Metastasis Staging, 2010–2013 11
Table 2: Market for Monoclonal Antibodies in Breast Cancer Therapeutics Market, US, Disease Stage at Diagnosis and Five-Year Relative Survival (%), 2013 12
Table 3: Breast Cancer Therapeutics, Global, All Pipeline Products (Discovery), 2013 61
Table 4: Breast Cancer Therapeutics, Global, All Pipeline Products (Preclinical), 2013 64
Table 5: Breast Cancer Therapeutics, Global, All Pipeline Products (IND/CTA-Filed and Phase I), 2013 76
Table 6: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase II), 2013 82
Table 7: Breast Cancer Therapeutics, Global, All Pipeline Products (Phase III), 2013 89
Table 8: Breast Cancer Therapeutics, Global, All Pipeline Products (Pre-Registration), 2013 92
Table 9: Market for Breast Cancer Therapeutics, Asia-Pacific, Forecast Data, 2013–2020 92
Table 10: Market for Breast Cancer Therapeutics, India, Forecast Data, 2013–2020 92
Table 11: Market for Breast Cancer Therapeutics, Australia, Forecast Data, 2013–2020 93
Table 12: Market for Breast Cancer Therapeutics, China, Forecast Data, 2013–2020 93
Table 13: Market for Breast Cancer Therapeutics, Japan, Forecast Data, 2013–2020 93

1.2 List of Figures

Figure 1: Breast Cancer Therapeutics Market, Global, Treatment Algorithm for Cancer Diagnosed at Stages I to III, 2013 16
Figure 2: Breast Cancer Therapeutics Market, Global, Treatment Algorithm for Cancer Diagnosed at Stage IV, 2013 17
Figure 3: Breast Cancer Therapeutics Market, Global, Heat Map (Marketed Products) 27
Figure 4: Breast Cancer Therapeutics Market, Global, Pipeline by Stage of Development and Program Type, 2013 29
Figure 5: Breast Cancer Therapeutics Market, Global, Pipeline by Molecule Type and Stage of Development, 2013 31
Figure 6: Breast Cancer Therapeutics Market, Global, Pipeline by Mechanism of Action and Stage of Development, 2013 33
Figure 7: Breast Cancer Therapeutics Market, Global, Clinical Trial Failure Rate (%), 2013 34
Figure 8: Breast Cancer Therapeutics Market, Global, Clinical Trial Size (Participants), 2013 36
Figure 9: Breast Cancer Therapeutics Market, Global, Clinical Trial Duration (months), 2013 37
Figure 10: Breast Cancer Therapeutics Market, Market Size ($m), 2013–2020 42
Figure 11: Breast Cancer Therapeutics Market, India, Market Size ($m), 2013–2020 44

Figure 12: Breast Cancer Therapeutics Market, Australia, Market Size ($m), 2013–2020 46
Figure 13: Breast Cancer Therapeutics Market, China, Market Size ($m), 2013–2020 48
Figure 14: Breast Cancer Therapeutics Market, Japan, Market Size ($m), 2013–2020 50
Figure 15: Breast Cancer Therapeutics Market, Global, Licensing Agreements, 2006–2013 53
Figure 16: Breast Cancer Therapeutics in APAC Market to 2020, Global, Licensing Agreements, 2006-2013 54
Figure 17: Breast Cancer Therapeutics in APAC Market to 2019, Global, Licensing Agreements, 2006-2013 55
Figure 18: Breast Cancer Therapeutics APAC Market to 2019, Global, Co-Development Deals, 2006-2013 57
Figure 19: Breast Cancer in APAC Market to 2019, Global, Co-Development Agreements, 2006-2013 58
Figure 20: GBI Research Market Forecasting Model 102

To order this report: Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options
http://www.reportlinker.com/p02126317/Breast-Cancer-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-HER-2-Positive-Therapies-Provide-Diversified-Treatment-Options.html

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker